Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3% – Time to Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares fell 3.3% during mid-day trading on Wednesday . The company traded as low as $68.73 and last traded at $68.94. 336,743 shares were traded during mid-day trading, a decline of 68% from the average session volume of 1,066,961 shares. The stock had previously closed at $71.29.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Jefferies Financial Group set a $125.00 price target on Structure Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 11th. Morgan Stanley lifted their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. Lifesci Capital upgraded shares of Structure Therapeutics to a “strong-buy” rating in a report on Monday, September 8th. Finally, Citigroup restated an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $99.11.

Structure Therapeutics Price Performance

The firm has a market cap of $4.23 billion, a price-to-earnings ratio of -57.16 and a beta of -1.64. The firm’s fifty day moving average is $40.36 and its 200-day moving average is $27.92.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). As a group, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Several large investors have recently modified their holdings of GPCR. Vestal Point Capital LP boosted its stake in Structure Therapeutics by 3.7% during the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company’s stock worth $30,967,000 after acquiring an additional 63,990 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of Structure Therapeutics by 7.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after buying an additional 106,389 shares during the period. Casdin Capital LLC increased its position in Structure Therapeutics by 26.9% in the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after buying an additional 330,000 shares in the last quarter. Millennium Management LLC raised its stake in Structure Therapeutics by 4.5% during the 3rd quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock worth $35,687,000 after buying an additional 54,496 shares during the period. Finally, Orbimed Advisors LLC raised its position in shares of Structure Therapeutics by 49.5% during the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after purchasing an additional 397,272 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.